CD8A and neoplasm: AH1-specific CD8+ T cells were also expanded in the spleens of CT26 tumor-bearing mice treated with anti-PD-1 and anti-CTLA-4, increasing from approximately 1% to an average of 15.6% of splenic CD8+ T cells (p<0.001, Fig 4E).